The immunomodulatory effects of probiotics and azithromycin in dextran sodium sulfate-induced ulcerative colitis in rats via TLR4-NF-κB and p38-MAPK pathway - ScienceDirect
Frontiers | Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Frontiers | Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch's postulates
Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records
Frontiers | Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records | Upsala Journal of Medical Sciences
PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
Genetic and dietary modulators of the inflammatory response in the gastro-intestinal tract of the BXD mouse genetic reference population
Frontiers | Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease - ScienceDirect
Frontiers | Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence
Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis | BMJ Open Gastroenterology
Frontiers | Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing
Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challeng | CEG
PDF) Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management | Journal of Crohn's and Colitis | Oxford Academic
Journal of Prescribing Practice - Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease
View of Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records | Upsala Journal of Medical Sciences
Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies - Calméjane - United European Gastroenterology Journal - Wiley Online Library
Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting | International Journal of Colorectal Disease
Frontiers | Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
Frontiers | The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies
Advances in Clinical and Experimental Medicine
Frontiers | Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Frontiers | Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial | Clinical Drug Investigation
PDF) Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Genetic and dietary modulators of the inflammatory response in the gastro-intestinal tract of the BXD mouse genetic reference population
